-
Lepu Medical Receives Approval for Noninvasive Blood Glucose Meter NeoGlu 01 in China
•
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions in China, has announced that it has received marketing approval from the National Medical Products Administration for its innovative product, NeoGlu 01, a noninvasive blood glucose meter. This new device combines optical and thermal methods…
-
Lepu Medical Secures Approval for RECATCHOR Catheter, Enhancing Cardiovascular Procedures
•
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions in China, has secured marketing approval from the National Medical Products Administration for its innovative RECATCHOR device. This anchored balloon dilation catheter is designed to facilitate the anchoring of guidewires and assist in the exchange…
-
Lepu Medical’s PeakHeat Vascular Sheath Gains Regulatory Green Light for Market Launch
•
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions in China, has secured marketing approval from the National Medical Products Administration for its PeakHeat disposable vascular sheath. This innovative product facilitates the percutaneous insertion of vascular systems, enabling the introduction of medical devices such…
-
Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released its financial report for 2023, reporting revenues of RMB 7.98 billion (USD 1.1 billion), a decrease of 24.78% year-on-year (YOY). The net profit attributable to shareholders of the listed company was RMB 1.26 billion (USD…
-
Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device
•
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, has received marketing approval from the National Medical Products Administration (NMPA) for its self-developed coronary mastoid balloon dilation catheter. The device, classified as a Category III medical device, is indicated for balloon dilation in…
-
Lepu Medical Secures NMPA Approval for Innovative Coronary Intravascular Impact Waveguide Tube
•
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a China-based provider of cardiovascular disease solutions, has received marketing approval from the National Medical Products Administration (NMPA) for its proprietary disposable coronary intravascular impact waveguide tube. This Category III device is now authorized for use in the pre-treatment and balloon dilation…
-
Lepu Medical Gains NMPA Approval for Semi-Automatic External Defibrillator
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its in-house developed semi-automatic external defibrillator. This approval marks a significant milestone in expanding Lepu’s portfolio of life-saving medical devices. The…
-
Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced receiving market approval from the National Medical Products Administration (NMPA) for its in-house developed MemoSorb biodegradable patent foramen ovale occluder. This innovative device is now approved for use in patients aged 18 to 60 with…
